THIRTYFIVEBIO LIMITED

Active Abingdon

Research and experimental development on biotechnology

8 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
T

THIRTYFIVEBIO LIMITED

Research and experimental development on biotechnology

Founded 26 Jan 2021 Active Abingdon, England 8 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 16 Oct 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 5 Feb 2026 Next due 8 Feb 2027 8 months remaining
Net assets £-12K £2M 2024 year on year
Total assets £985K £2M 2024 year on year
Total Liabilities £997K £588K 2024 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

99 Park Drive Milton Abingdon OX14 4RY England

Telephone

0800 000 0000

Website

www.example.com

Full company profile for THIRTYFIVEBIO LIMITED (13157735), an active life sciences and medical technology company based in Abingdon, England. Incorporated 26 Jan 2021. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type total-exemption-full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2021–2024)

Cash in Bank

£353.08k

Decreased by £1.60M (-82%)

Net Assets

-£11.67k

Decreased by £2.41M (-100%)

Total Liabilities

£996.84k

Increased by £588.27k (+144%)

Turnover

N/A

Employees

8

Increased by 2 (+33%)

Debt Ratio

101%

Increased by 86 (+573%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 2

Investors (5)

Investor NameInvestor SinceParticipating Rounds
Investor 4Apr 2021Seed
Investor 5Apr 2021Seed
Investor 1Apr 2025Bridge/Convertible

Share Capital

Share Capital

Share allotments and capital structure

8 Allotments 452,321 Shares £234k Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
26 Feb 202541,022£4.102£0
17 Jan 20248,168£0.817£0
10 Nov 20226,534£4k£0.653
4 Apr 202244,432£4.443£0
21 Feb 202296,826£9.683£0

Officers

Officers

1 active 2 resigned
Status
Nils LonbergDirectorAmericanUnited States7028 May 2021Active

Shareholders

Shareholders (37)

Canaan Xii L.p., Acting By Its General Partner, Canaan Partners Xii Llc
47.3%
1,929,578
Canaan 2020+ Co-investment L.p., Acting By Its General Partner, Canaan Partners 2020+ Co-investment Llc, Acting By Its Manager Canaan Management Llc
20.7%
845,070

Persons with Significant Control

Persons with Significant Control (0)

No PSC information available

Group Structure

Group Structure

THIRTYFIVEBIO LIMITED Current Company
TFBIO LIMITED united kingdom

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
28 May 2026IncorporationMemorandum Articles
28 May 2026ResolutionResolutions
27 May 2026CapitalCapital Name Of Class Of Shares
16 Feb 2026CapitalCapital Cancellation Shares
16 Feb 2026CapitalCapital Return Purchase Own Shares
28 May 2026 Incorporation

Memorandum Articles

28 May 2026 Resolution

Resolutions

27 May 2026 Capital

Capital Name Of Class Of Shares

16 Feb 2026 Capital

Capital Cancellation Shares

16 Feb 2026 Capital

Capital Return Purchase Own Shares

Recent Activity

Latest Activity

Memorandum Articles

5 days ago on 28 May 2026

Resolutions

5 days ago on 28 May 2026

Capital Name Of Class Of Shares

6 days ago on 27 May 2026

Capital Cancellation Shares

3 months ago on 16 Feb 2026

Capital Return Purchase Own Shares

3 months ago on 16 Feb 2026